stockrow
Saturday 7 November 2026
Export NTLA’s income statement to Excel — free account
Intellia Therapeutics, Inc.
NTLA Healthcare Biotechnology
Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024.
- Revenue
- −48.0%
- EPS
- +1.09%
- Free cash flow
- −11.1%
Quarter to September 2026, against a year earlier
11.35
0.25
+2.25%
Follow NTLA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.48%) | (56.34%) | (55.44%) | (62.60%) | |
Piotroski F-Score |
4 | 5 | 5 | 4 | |
| (40.60%) | (45.23%) | (45.55%) | (46.63%) | ||
ROIC |
(124.43%) | (107.35%) | (91.28%) | (195.32%) | |
Return on Tangible Assets |
(93.48%) | (97.31%) | (86.29%) | (96.86%) | |
Average Days of Receivables |
51.07 | 50.43 | 44.91 | 51.75 | |
Free Cash Flow per Share |
(3.65) | (3.07) | (2.61) | (2.53) | |
Free Cash Flow |
(395.86) | (363.62) | (348.60) | (355.17) | |
Capital Expenditures |
(1.13) | (0.47) | (1.95) | — | |
| Other line items | |||||
Cash ROIC |
(35.30%) | (36.47%) | (29.91%) | (32.67%) | |
Accounts Receivable Turnover |
7.53 | 6.73 | 6.37 | 5.70 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
574.63% | 546.47% | 582.68% | 634.05% | |
Selling, General and Administrative Expense of Revenue |
177.03% | 190.09% | 228.98% | 287.19% | |
Share Based Compensation of Revenue |
118.54% | 108.72% | 114.10% | 118.53% | |
Operating CF/Net income |
0.96 | 0.92 | 0.87 | 0.83 | |
Depreciation/Fixed assets |
0.90 | 1.01 | 1.01 | 0.00 | |
Capex/Depreciation |
(0.07) | (0.03) | (0.13) | — | |
Revenue per Share |
0.62 | 0.56 | 0.45 | 0.38 | |
Operating CF per Share |
(3.64) | (3.06) | (2.60) | (2.53) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.03 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026